<DOC>
	<DOCNO>NCT01775423</DOCNO>
	<brief_summary>This open label , single arm , dose escalation study BBI608 patient advanced malignancy .</brief_summary>
	<brief_title>A Study BBI608 Adult Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion Criteria 1 . Signed write informed consent must obtain document accord International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) , local regulatory requirement , permission use private health information accordance Health Insurance Portability Accountability Act ( HIPPA ) prior studyspecific screening procedure 2 . For solid tumor lymphoma , histologically cytologically confirm solid tumor metastatic , unresectable , recurrent standard curative palliative therapy exist longer effective . 3 . ≥ 18 year age 4 . For solid tumor , measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) 5 . For lymphoma , measurable disease define International Workshop Standardize Response Criteria NonHodgkin 's Lymphoma 6 . For multiple myeloma , measurable disease define International Uniform Response Criteria Multiple Myeloma 7 . Karnofsky performance status great equal 70 % 8 . Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last BBI608 dose 9 . Females childbearing potential must negative serum pregnancy test 10 . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) less equal 1.5 × upper limit normal ( ULN ) 11 . Hemoglobin ( Hgb ) great equal 10 g/dl 12 . Total bilirubin less equal 1.5 × ULN 13 . Creatinine le equal 1.5 x ULN creatinine clearance great 60 mL/min/1.73 m2 patient creatinine level institutional normal . Creatinine &lt; 2.5 x ULN multiple myeloma patient . 14 . Absolute neutrophil count great equal 1.5 x 109/L 15 . Platelets great equal 100 x 109/L 16 . Life expectancy great equal 3 month Exclusion Criteria 1 . Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within four week first dose exception single dose radiation 8 Gray ( equal 800 RAD ) palliative intent pain control 14 day begin administration BBI608 . 2 . Surgery within 4 week prior first dose 3 . Any known untreated brain metastasis . Treated subject must stable 4 week completion treatment , image documentation require . Patients must clinical symptom brain metastasis must either steroids stable dose steroid least 2 week prior protocol enrollment . Patients know leptomeningeal metastasis exclude , even treat . 4 . Pregnant breastfeed 5 . Significant gastrointestinal disorder ( ) , opinion Principal Investigator , ( e.g. , Crohn 's disease , ulcerative colitis , extensive gastric small intestine resection ) 6 . Unable unwilling swallow BBI608 capsule daily 7 . Uncontrolled intercurrent illness include , limited ongoing active infection , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>